Бинго! Не трогает ее. Не волнует вообще. Как таких бездушных людей земля носит и еще детей им дает, непонятно?

а у вас какая точка зрения? маски вам не надо, вакцины не надо. Вы что конкретно предлагаете, кроме нагугленных статей с интернета?

.

_________________
На форуме с 2010 .

в чем тут связь? ну и ладно. про дураков уже было сказано.
речь о пандемии, еще раз. которая перeдается воздушно- капельным путем.
опять 25

само пройдет, схлынет как волна.
глупо?

_________________
Some things can never be unsaid, so don’t say them in the first place.
If it were not for British news sources, I would never know what was really going on here in the States.

Так наденьте маску , и отойдите .
Если ВЫ считаете что это вас защитит.

_________________
На форуме с 2010 .

ну во общем ,прдолжйте этот детский утренник без меня

Аварию не всегда можно предотвратить. Они случаются поневоле. А ковид можно предотвратить надев маску! Это в вашем контроле.
Даже если вы лично не верите в серьезность вируса, то, если вы человек добрый и с эмпатией, то должны уважать право других на личную безопасность.
Если вы не носите маску - вы нарушаете право других людей на безопасность. Вот и все. Ваша личная свобода в таком случае нарушает права других людей.
А тут уже вам решать, что для вас важнее: личная свобода, или безопасность окружающих. Похоже вы уже сделали всой выбор.

Тебе любой вирусолог и иммунолог скажет , прививка защитит тебя на 70% от кори , даст легче перенести , но это тоже не факт на 100%,
но увеличит шансы диабета НАПРИМЕР .
Прививка , на 80% защитит тебя от краснухи , но шанс что у тебя появятся аутоиммунные заболевания увеличится.
Это написано даже в инструкции - как побочка.
Это уж тебе решать , корь или диабет , краснуха или аллергия -пожизненно ,

_________________
На форуме с 2010 .

Какой смысл развитым странам гробить локдаунами свои экономики сейчас? Назад то фарш не провернуть. Ладно там Россия она в жопу 8 лет чалит. А ведущие страны? Дать коммунистическому Китаю рвануть перёд а самим упасть на дно депрессии ?

Ну хорош уже, перегибаете

Я лично верю в серьезность вируса .
Но я не верю цифрам которые предлагает ВОЗ .
Далее я не верю в эффективность масок и локдаунлв .
Они научно не подтверждены .
Вот например локдаунов не было в Швеции , и масок тоже , поинтересуйтесь , и это не повлияло на статистику смертности .

_________________
На форуме с 2010 .

Говоря о витаминах ;

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study"
Abstract

Objective: The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly increase serum 25OHD concentration. We therefore evaluated the effect of calcifediol treatment, on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19.

Design: Parallel pilot randomized open label, double-masked clinical trial.

Setting: University hospital setting (Reina Sofia University Hospital, Córdoba Spain.) PARTICIPANTS: 76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1).

Procedures: All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 h on the first day, and 200 mg every 12 h for the following 5 days), azithromycin (500 mg orally for 5 days. Eligible patients were allocated at a 2 calcifediol:1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol (0.532 mg), or not. Patients in the calcifediol treatment group continued with oral calcifediol (0.266 mg) on day 3 and 7, and then weekly until discharge or ICU admission. Outcomes of effectiveness included rate of ICU admission and deaths.

Results: Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50 %) p value X2 Fischer test p < 0.001. Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95 %CI 0.002-0.17). Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension and T2DM): 0.03 (95 %CI: 0.003-0.25). Of the patients treated with calcifediol, none died, and all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.

Conclusion: Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.

Keywords: 1α, 25(OH)2D or 1α, 25-dihydroxyvitamin D or calcitriol; Acute respiratory distress syndrome (ARDS); COVID-19; Calcifediol or 25-hydroxyvitamin D3; Cathelicidin peptide; Chloroquine; Covidiol; Cuboidal alveolar coating cells type II; Cytokine/Chemokine storm; Defensins; Hydroxychloroquine; Hypercoagulability; Neutrophil activity; Renin-angiotensin system; SARS-CoV-2; TLR co-receptor CD14; Vitamin D; Vitamin D endocrine system; Vitamin D receptor; Vitamin D3 or cholecalciferol.

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures


https://pubmed.ncbi.nlm.nih.gov/32871238/

_________________
На форуме с 2010 .

EARLY VIRAL CLEARANCE AMONG COVID-19 PATIENTS WHEN GARGLING WITH POVIDONE-IODINE AND ESSENTIAL OILS: A PILOT CLINICAL TRIAL

NURUL AZMAWATI MOHAMED, NIZAM BAHAROM, WAN SHAHIDA WAN SULAIMAN, ZETTI ZAINOL RASHID, KON KEN WONG, UMI KALSOM ALI, SITI NORLIA OTHMAN, MUTTAQILLAH NAJIHAN ABD SAMAD, NAJMA KORI, PETRICK PERIYASAMY, NOR AZIZAN ZAKARIA, AGNI NHIRMAL KUMAR SUGUMAR, NUR EZZATY MOHAMMAD KAZMIN, XIONG KHEE CHEONG, SITI MARIYAM SANIMAN, ILINA ISAHAK
doi: https://doi.org/10.1101/2020.09.07.20180448
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
AbstractInfo/HistoryMetrics Preview PDF
Abstract

Background: Gargling had been reported to have significant roles in the prevention and treatment of respiratory tract infections. The purpose of this study was to assess the ability of regular gargling to eliminate SARS-CoV-2 in the oropharynx and nasopharynx. Methodology: This pilot, open labeled, randomized, parallel study compared the effect of 30 seconds, 3 times/day gargling using 1% povidone-iodine (PVP-I), essential oils and tap water on SARS-CoV-2 viral clearance among COVID-19 patients in a tertiary hospital in Kuala Lumpur. Progress was monitored by day 4,6 and 12 PCR (Ct value), gargling and symptoms diary as well as clinical observations. Results: Five confirmed Stage 1 COVID-19 patients were recruited for each arm. The age range was from 22 to 56 years old. The majority were males. Two respondents had co-morbidities, which were asthma and obesity. Viral clearance was achieved at day 6 in 100%, 80%, 20% and 0% for 1% PVP-I, essential oils, tap water and control group respectively. Analysis of 1% PVP-I group versus control group showed significant p-value for comparison of PCR results on Day 4, Day 6 and Day 12. Conclusions: This preliminary study showed that gargling with 1% PVP-I and essential oils show great potential to be part of the treatment and management of Stage 1 COVID-19. Larger studies are required to ascertain the benefit of gargling for different stages of COVID-19 patients. This study was registered in clinicaltrial.gov (NCT04410159).

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

clinicaltrial.gov (NCT04410159)

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT04410159?cond=gargle+covid&draw=2&rank=7

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study received approval from the Research and Ethics Committee, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM PPI/111/8/JEP-2020-372).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

https://www.medrxiv.org/content/10.1101/2020.09.07.20180448v1

_________________
На форуме с 2010 .

таак, и последний вопрос.
С какой целью вы вылезли из песочницы?